natgillin/translations-raw huggingface dataset:
Timeline Event Date Adoption of Audit Planning Memorandum (APM) / Start of audit 4.7.2018 / 3.9.2018 Official sending of draft report to Commission (or other auditee) 28.6.2019 Adoption of the final report after the adversarial procedure 25.9.2019 Commission’s (or other auditee’s) official replies received in all languages 31.10.2019 
Časovnica Dogodek Datum Sprejetje revizijskega memoranduma / začetek revizije 4. julij 2018 / 3. september 2018 Uradno posredovanje osnutka poročila Komisiji (ali drugemu revidirancu) 28. junij 2019 Sprejetje končnega poročila po razčiščevalnem postopku 25. september 2019 Prejeti uradni odgovori Komisije (ali drugih revidirancev) v vseh jezikih 31. oktober 2019
© European Union, 2019. 
4© Evropska unija, 2019.
EN PDF ISBN 978-92-847-3640-9 doi:10.2865/0477 QJ-AB-19-014-EN-N EN HTML ISBN 978-92-847-3665-2 doi:10.2865/845238 QJ-AB-19-014-EN-Q 
SL PDF ISBN 978-92-847-3646-1 doi:10.2865/20475 QJ-AB-19-014-SL-N SL HTML ISBN 978-92-847-3660-7 doi:10.2865/823740 QJ-AB-19-014-SL-Q
INEA’s mission is to support the Commission, project promoters and stakeholders by providing expertise and programme management to infrastructure, research and innovation projects in the fields of transport, energy and telecommunications and to promote synergies between these activities. 
50 Poslanstvo agencije INEA je podpirati Komisijo, nosilce projektov in deležnike z zagotavljanjem strokovnega znanja in upravljanja programov v okviru infrastrukturnih, raziskovalnih in inovacijskih projektov na področju prometa, energetike in telekomunikacij ter spodbujati sinergije med temi dejavnostmi.
INEA has been entrusted with 93 % of the total CEF budget and 7 % of the H2020 budget. 
Agenciji INEA je bilo zaupanih 93 % celotnega proračuna IPE in 7 % proračuna programa Obzorje 2020.
We found shortcomings in the otherwise well organised CEF selection procedures, risks in the implementation of the programme and weaknesses in performance reporting. 
Ugotovilo je pomanjkljivosti v sicer dobro organiziranih izbirnih postopkih IPE, tveganja pri izvajanju programa ter slabosti pri poročanju o smotrnosti.
We make recommendations to Commission and INEA aimed at improving the potential for synergies, strengthening the framework for INEA’s management of the delegated programmes, ensuring greater harmonisation and transparency of the CEF project selection procedures, setting better conditions for timely implementation of the CEF and redesigning the performance framework to better monitor CEF project results. 
Sodišče izreka priporočila Komisiji in agenciji INEA, namenjena izboljšanju možnosti za nastanek sinergij, krepitvi okvira, v skladu s katerim agencija INEA upravlja prenesene programe, zagotavljanju večje usklajenosti in transparentnosti postopkov za izbiro projektov IPE, določanju boljših pogojev za pravočasno izvajanje IPE in preoblikovanju okvira smotrnosti za boljše spremljanje rezultatov projektov IPE.
ECA special report pursuant to Article 287(4), second subparagraph, TFEU. 50 
Posebno poročilo Sodišča v skladu z drugim pododstavkom člena 287(4) PDEU.
EN 2019 Special Report 21 Addressing antimicrobial resistance: progress in the animal sector, but this health threat remains a challenge for the EU NO 
SL 2019 Posebno poročilo 21 Obravnavanje protimikrobne odpornosti: napredek v živinorejskem sektorju, vendar je ta nevarnost za zdravje še vedno izziv za EU št.
Executive summary I Antimicrobial resistance (AMR) - when microbes develop resistance against medicines that were previously able to fight them - is a growing threat to global health. 
Povzetek I Protimikrobna odpornost – to, da se pri mikrobih razvije odpornost proti zdravilom, s katerimi se je bilo prej mogoče boriti proti njim – je vse večja nevarnost za svetovno zdravje.
The European Centre for Disease Prevention and Control reported that it already leads to 33 000 deaths each year in the EU/EEA, mostly due to infections in hospitals and other healthcare settings. 
Po poročilih Evropskega centra za preprečevanje in obvladovanje bolezni v EU/EGP že povzroči 33 000 smrti na leto, predvsem zaradi bolnišničnih okužb in okužb v drugih zdravstvenih okoljih.
The World Health OrganisationŐs ŇOne HealthÓ principle, which considers human health, animal health and the environment, recognises that an integrated approach to antimicrobials is needed. 
Z načelom Svetovne zdravstvene organizacije (v nadaljnjem besedilu: SZO) „eno zdravje”, pri katerem sta upoštevana zdravje ljudi in živali ter okolje, se priznava, da je potreben celosten pristop k antimikrobikom.
II Fighting against antimicrobial resistance is complicated. 
II Zoper protimikrobno odpornost se ni lahko boriti.
It is challenging to apply good infection prevention and control measures in practice (including practices as basic as hand washing). 
Težko je doseči, da se v praksi uporabljajo dobri ukrepi za preprečevanje in obvladovanje okužb (vključno z osnovnimi praksami, kot je umivanje rok).
It is also challenging to use existing antimicrobials prudently (both to treat humans and animals), meaning using the right drug correctly and only when needed. 
Prav tako je težko preudarno uporabljati obstoječe antimikrobike (tako za zdravljenje ljudi kot živali), kar pomeni pravilno uporabljati pravo zdravilo le takrat, ko je to potrebno.
Finally, no new classes of antibiotics have been discovered for many years. 
Že mnogo let namreč ni bil odkrit noben nov razred antibiotikov.
III In the EU, human health is a Member State competence. 
III V EU je zdravje ljudi v pristojnosti posameznih držav članic.
Article 6 and 168 of the Treaty on the Functioning of the European Union give the Union a mandate to support, coordinate, supplement and encourage cooperation between Member States for the protection and improvement of human health. 
V skladu s členoma 6 in 168 Pogodbe o delovanju Evropske unije je Unija pristojna za podpiranje, usklajevanje, dopolnjevanje in spodbujanje sodelovanja med državami članicami za namene varovanja in izboljšanja zdravja ljudi.
Antimicrobial resistance is recognised by EU law as a serious cross-border threat to health, where EU action is required. 
Protimikrobna odpornost je glede na zakonodajo EU resna čezmejna nevarnost za zdravje, pri kateri je potrebno ukrepanje EU.
Furthermore, there is clear Commission competence to act in veterinary issues, food safety, and research: all of which are relevant for antimicrobial resistance. 
Poleg tega ima Komisija jasno pristojnost, da ukrepa pri zadevah, povezanih z veterinarsko medicino, varnostjo hrane in raziskavami, ki so vse pomembne za protimikrobno odpornost.
IV Our audit considered the rising threat of antimicrobial resistance and recent EU policy initiatives. 
IV Z revizijo Sodišča so bile obravnavane vse večja nevarnost, ki jo ta odpornost pomeni, in nedavne politične pobude EU.
We examined how the Commission and the European Centre for Disease Prevention and Control (ECDC) managed resources aimed at supporting Member States One Health approach to antimicrobial resistance, and whether the framework to improve the prudent use of veterinary antimicrobials and monitor antimicrobial resistance in food was being well applied. 
Sodišče je preučilo, kako sta Komisija in Evropski center za preprečevanje in obvladovanje bolezni (v nadaljnjem besedilu: ECDC) upravljala vire, namenjene podpori državam članicam pri pristopu k protimikrobni odpornosti po načelu „eno zdravje”, ter ali se dobro izvajata okvir za izboljšanje preudarne uporabe antimikrobikov v veterinarski medicini in spremljanje protimikrobne odpornosti v živilih.
We also examined how the Commission supported AMR related research. 
Preučilo je tudi, kako Komisija podpira raziskave, povezane s protimikrobno odpornostjo.
V We conclude that the activities of the Commission and agencies have led to some progress, for example, in veterinary and food related issues. 
V Sodišče zaključuje, da so dejavnosti Komisije in agencij prinesle nekaj napredka, na primer pri zadevah, povezanih z veterinarsko medicino in hrano.
However, there is little evidence to date that the health burden of AMR has been reduced in the European Union. 4 
Vendar je doslej malo dokazov, da je bilo zdravstveno breme, ki ga povzroča protimikrobna odpornost, v Evropski uniji zmanjšano. 4
VI The Commission and ECDC support to strengthen Member States One Health approach to AMR was valuable, but had resulted in little demonstrable progress in reducing AMR. 
VI Podpora Komisije in centra ECDC za okrepitev pristopa k protimikrobni odpornosti po načelu „eno zdravje” v državah članicah je bila dragocena, posledični dokazljivi napredek pri zmanjšanju protimikrobne odpornosti pa je bil majhen.
The Joint Action on antimicrobial resistance, to support national One Health policies, facilitated cooperation between Member States but faced challenges to the sustainable implementation of its results. 
Skupni ukrep na področju protimikrobne odpornosti, namenjen podpori nacionalnih politik po načelu „eno zdravje”, je omogočil lažje sodelovanje med državami članicami, vendar so se pri trajnostnem izvajanju njegovih rezultatov pojavljali izzivi.
A recent Commission funded study led by the OECD was a compass for cost effective options for Member States to reduce antimicrobial resistance in hospitals and other healthcare settings. 
Nedavna raziskava, ki jo je financirala Komisija, vodila pa Organizacija za gospodarsko sodelovanje in razvoj (v nadaljevanju: OECD), je pokazala državam članicam pot k stroškovno učinkovitim možnostim za zmanjšanje protimikrobne odpornosti v bolnišnicah in drugih zdravstvenih okoljih.
Outcome indicators were not consistently used by the Member States we visited, or by the Commission, to monitor progress; data on health care associated infections, which are the primary source of AMR infections, was incomplete; and, at the time of our audit, there was insufficient knowledge about AMR in the environment. 
Države članice, ki jih je obiskalo Sodišče, in Komisija niso dosledno uporabljale kazalnikov izidov za spremljanje napredka. Podatki o okužbah, povezanih z zdravstveno oskrbo, ki so glavni vir okužb, povezanih s protimikrobno odpornostjo, niso bili popolni in v času revizije Sodišča je bilo delovanje te odpornosti v okolju premalo poznano.
VII The prudent use of veterinary antimicrobials is generally improving in the Member States. 
VII Antimikrobiki za uporabo v veterinarski medicini se v državah članicah na splošno uporabljajo vedno preudarneje.
Between 2011 and 2016, sales of veterinary antimicrobials reduced by 20 %. 
Med letoma 2011 in 2016 se je prodaja antimikrobikov za tako uporabo zmanjšala za 20 %.
However, there are big differences between the Member States, and consumption of some antimicrobials is still too high. 
Vendar so med državami članicami velike razlike, poraba nekaterih antimikrobikov pa je še vedno prevelika.
Recent EU legislation on medicinal products and feed addressed some known weaknesses. 
V nedavno sprejeti zakonodaji EU o zdravilih in krmi so bile obravnavne nekatere znane slabosti.
The future Common Agricultural Policy provides an opportunity to further strengthen the EU framework for dealing with AMR. 
Prihodnja skupna kmetijska politika je priložnost za nadaljnjo krepitev okvira EU za obravnavanje protimikrobne odpornosti.
Funding from the EU budget is a major source of investment for research, and has created structures to speed up the development of new antimicrobials. 
Financiranje iz proračuna EU je pomemben vir naložb v raziskave in z njim so bile ustvarjene strukture za pospešitev razvoja novih antimikrobikov.
But EU funded public Đ private research initiatives experienced delays, and there have been no breakthroughs yet. 
Vendar pa je prihajalo pri pobudah za javno–zasebne raziskave, ki jih financira EU, do zamud in doslej še ni bilo pomembnih prebojev.
The Commission has not comprehensively evaluated its approach to antimicrobial research, and its action plan does not address some of the specific challenges facing AMR research. 
Komisija svojega pristopa k raziskavam na področju antimikrobikov ni celovito ocenila in v njenem akcijskem načrtu niso obravnavani nekateri posebni izzivi za raziskave na področju protimikrobne odpornosti.
Concrete initiatives to address market failures affecting provision of new antimicrobials are largely absent. 
Konkretnih pobud za obravnavo nedelovanja trga, ki vpliva na dobavo novih antimikrobikov, v glavnem ni.
IX Based on our conclusions, we make recommendations aimed at strengthening the CommissionŐs response to antimicrobial resistance through better support to Member States; promoting the prudent use of antimicrobials and better monitoring of antimicrobial resistance; and strengthening strategies for research. 5 
IX Sodišče je na podlagi svojih zaključkov dalo priporočila, katerih namen je povečanje odziva Komisije na protimikrobno odpornost z boljšim podpiranjem držav članic, spodbujanjem preudarne uporabe antimikrobikov in boljšim spremljanjem protimikrobne odpornosti ter krepitvijo strategij za raziskave. 5
Introduction What is Antimicrobial Resistance 01 Antimicrobials are used to treat people, animals and plants. 
Uvod Kaj je protimikrobna odpornost 01 Antimikrobiki se uporabljajo za zdravljenje ljudi, živali in rastlin.
Antimicrobial resistance (AMR) happens when microbes (bacteria, viruses, parasites, and fungi) develop resistance against medicines that were previously able to fight them, making the treatment less efficient or completely ineffective. 
Protimikrobna odpornost se pojavi, če mikrobi (bakterije, virusi, zajedavci in glive) razvijejo odpornost proti zdravilom, s katerimi se je bilo pred tem mogoče boriti proti njim, zaradi česar je zdravljenje manj učinkovito ali popolnoma neučinkovito.
AMR develops naturally over time, usually through genetic changes1, but it accelerates when antimicrobials are overused or misused i.e. are not used prudently Đ meaning the right drug is used when needed, at the right dose, frequency, and duration (Figure 1 shows how AMR develops). 
Sčasoma se razvije po naravni poti, navadno zaradi genskih sprememb1, vendar se razvoj pospeši ob prekomerni ali nepravilni uporabi antimikrobikov, tj. uporabi, ki ni preudarna. Uporaba je preudarna takrat, ko se ustrezno zdravilo uporablja, ko je potrebno, v pravem odmerku, pogostosti in trajanju (na sliki 1 je ponazorjeno, kako se razvije protimikrobna odpornost).
Figure 1 Đ How antimicrobial resistance develops High number of bacteria including good bacteria (protecting body from illness), bacteria causing illness and few resistant bacteria. 
Slika 1 – Kako se razvije protimikrobna odpornost Veliko število bakterij, vključno z dobrimi (ki telo ščitijo pred boleznijo), bakterije, ki povzročajo bolezen in malo odpornih bakterij.
Antibiotics kills off all bacteria (the good ones and ones causing the illness) except the antibiotic resistant bacteria. 
Antibiotiki uničijo vse bakterije (dobre in tiste, ki povzročajo bolezen), razen bakterij, ki so odporne proti antibiotikom.
Drug resistant bacteria can transfer its mutation to other bacteria. 
Bakterije, odporne proti zdravilom, lahko svojo mutacijo prenesejo na druge bakterije.
Source: ECA based on United States Centers for Disease Control and Prevention (CDC). 02 The World Health Organisation (WHO) identified AMR as a serious threat to global health, development and food security2. 
Vir: Evropsko računsko sodišče na podlagi centrov ZDA za obvladovanje in preprečevanje bolezni 02 Svetovna zdravstvena organizacija (SZO) je protimikrobno odpornost opredelila kot resno nevarnost za svetovno zdravje, razvoj in varnost hrane2.
The European Centre for Disease Prevention and Control (ECDC) reported3 that 33 000 people die each year, based on Antimicrobial resistance Đ Key facts, WHO, February 2018. 
Po poročilih Evropskega centra za preprečevanje in obvladovanje bolezni (ECDC)3 na podlagi podatkov iz leta 2015 v EU/Evropskem gospodarskem prostoru (EGS) vsako leto umre Antimicrobial resistance – Key facts, SZO, februar 2018.
WHO (2017), Antibiotic Resistance Fact Sheet, World Health Organization. 
SZO (2017), Antibiotic Resistance Fact Sheet, Svetovna zdravstvena organizacija.
Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015, the Lancet, 2018. 
Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015, the Lancet, 2018.
2015 data, in the EU / European Economic Area (EEA) from infections caused by drug resistant bacteria. 
33 000 ljudi zaradi okužb, ki jih povzročijo bakterije, odporne na zdravila.
AMR generates additional yearly costs of Ű1.5 billion4 due to extra healthcare costs and productivity losses. 
Protimikrobna odpornost povzroča dodatne letne stroške v višini 1,5 milijarde EUR4 zaradi dodatnih zdravstvenih stroškov in izgube produktivnosti.
Infections caused by organisms that have developed resistance, usually acquired in hospitals and other healthcare settings, may require lengthier and costlier treatments, some with serious side effects (e.g. renal failure), and carry a higher risk of death for patients. 
Do okužb, povzročenih z organizmi, ki so razvili odpornost, pride običajno v bolnišnicah in drugih zdravstvenih okoljih, zanje pa je lahko potrebno dolgotrajnejše in dražje zdravljenje; pri nekaterih se pojavijo resni stranski učinki (npr. odpoved ledvic) in pomenijo večje tveganje za smrt bolnika.
03 Nearly 40 % of the health burden of AMR is caused by bacteria resistant to last-line antibiotics (such as carbapenems and colistin). 
03 Skoraj 40 % zdravstvenega bremena zaradi protimikrobne odpornosti povzročijo bakterije, ki so odporne na antibiotike zadnje obrambne linije (na primer karbapeneme in kolistin).
When last-line antibiotics are no longer effective, it is difficult and may be impossible to treat infected patients5. 
Kadar antibiotiki zadnje obrambne linije niso več učinkoviti, je težko in morda nemogoče zdraviti okužene bolnike5.
04 In the EU / EEA, about two thirds of total antimicrobial use is for food producing animals6. Some of these then end up in the environment7. 
04 V EU/EGS se približno dve tretjini vseh antimikrobikov uporablja za živali za proizvodnjo živil6, del njih pa se nato znajde v okolju7.
There is evidence that reductions in the use of antimicrobials in food-producing animals lead to reductions in the presence of antimicrobial-resistant microorganisms in these animals8. 
Obstajajo dokazi, da zmanjšanje uporabe antimikrobikov pri živalih za proizvodnjo živil pri teh živalih povzroči zmanjšanje prisotnosti mikroorganizmov, odpornih na antimikrobike8.
05 Antimicrobials used to treat diseases that can be transmitted between animals and humans, such as campylobacteriosis and salmonellosis, are becoming less effective. 
05 Antimikrobiki za uporabo pri zdravljenju bolezni, ki se lahko prenašajo med živalmi in ljudmi, kot so kampilobakterioza in salmoneloza, postajajo manj učinkoviti.
Resistance to certain antimicrobials varies between different countries and type of microorganisms. 
Odpornost proti nekaterim antimikrobikom se med posameznimi državami in vrstami mikroorganizmov razlikuje.
EU Action on Antimicrobial Resistance, European Commission, 2017. 
Ukrepanje EU na področju protimikrobne odpornosti, Evropska komisija, 2017.
ECDC infographic on AMR, November 2018. 
ECDC infographic on AMR, november 2018.
See Table 5 of the most recent JIACRA report (from 2017) on the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food producing animals. 
Glej tabelo 5 najnovejšega poročila o skupni medagencijski analizi porabe protimikrobnih sredstev in protimikrobne odpornosti (iz leta 2017) o uživanju protimikrobnih sredstev in pojavu protimikrobne odpornosti pri človeških bakterijah in pri bakterijah živali, ki so namenjene za proizvodnjo živil.
See, for example WHO guidelines on use of medically important antimicrobials in food-producing animals and How do we reduce antibiotic resistance from livestock?, Hannah Ritchie, Our World in Data, November 2017. 
Glej na primer WHO guidelines on use of medically important antimicrobials in food-producing animals in How do we reduce antibiotic resistance from livestock?, Hannah Ritchie, Our World in Data, november 2017.
See, for example, ŇRestricting the use of antibiotics in food-producing animals and its associations with antibiotic resistance in food-producing animals and human beings: a systematic review and meta-analysisÓ, The Lancet, November 2017; or ŇWHO calls on food industry to stop routinely using antibiotics in healthy animalsÓ, The Pharmaceutical Journal, November 2017. 
Glej na primer, Restricting the use of antibiotics in food-producing animals and its associations with antibiotic resistance in food-producing animals and human beings: a systematic review and meta-analysis, The Lancet, november 2017 ali WHO calls on food industry to stop routinely using antibiotics in healthy animals, The Pharmaceutical Journal, november 2017.
7 4 5 6 7 8 
7 4 5 6 7 8
Why fighting AMR is complicated 06 The continued overuse or misuse of antimicrobials in the human and animal health sectors accelerates the development of antimicrobial resistance. 
Zakaj je boj zoper protimikrobno odpornost zapleten 06 Stalna prekomerna ali nepravilna uporaba antimikrobikov v sektorjih zdravja ljudi in živali pospešuje razvoj protimikrobne odpornosti.
The ECDC has reported some reductions in the consumption of antimicrobials for human health, with significant variations between Member States9. 
ECDC je poročal o nekaterih zmanjšanjih porabe antimikrobikov za zdravje ljudi, pri čemer so med državami članicami bistvene razlike9.
The prevention and control of cross-transmission of antimicrobial-resistant microorganisms in healthcare settings, in particular hospitals and long-term care facilities, is important. 
Pomembna sta preprečevanje in obvladovanje navzkrižnega prenosa mikroorganizmov, odpornih proti antimikrobikom, v zdravstvenih okoljih, zlasti bolnišnicah in ustanovah za dolgotrajno oskrbo.
However, it is a challenge to ensure good infection prevention and control measures (such as hand hygiene, contact precautions, patient isolation, and cleaning) in practice. 
Vendar je v praksi težko zagotoviti dobre ukrepe za preprečevanje in obvladovanje okužb (kot so higiena rok, varnostni ukrepi pri stiku, izolacija bolnikov in čiščenje).
These measures require training, resources, and supervision across healthcare facilities; and need to be applied rigorously by the hundreds of thousands of healthcare personnel in the EU. 
Za te ukrepe so potrebni usposabljanje, viri in nadzor v vseh zdravstvenih ustanovah, na stotine tisočev zdravstvenih delavcev v EU pa jih mora strogo upoštevati.
In addition, ECDC data indicates that basic diagnostic tests in hospitals, required to target medical treatments, are not being carried out across the EU as often as necessary. 
Poleg tega podatki centra ECDC kažejo, da se osnovni diagnostični testi v bolnišnicah, ki so potrebni za ciljno zdravljenje, v EU ne izvajajo tako pogosto, kot bi bilo potrebno.
This also contributes to the excessive use of broad-spectrum antibiotics. 
To prispeva tudi k prekomerni uporabi antibiotikov širokega spektra.
Figure 2 illustrates how AMR can spread. 
Na sliki 2 je ponazorjeno, kako se lahko širi protimikrobna odpornost.
8 9 ŇAntimicrobial consumption Đ Annual epidemiological Report for 2017Ó, ECDC, 2018. 
8 9 Antimicrobial consumption – Annual epidemiological Report for 2017, ECDC, 2018.
Figure 2 Đ How resistance to antibiotics spreads Antibiotics provide a cure for bacterial infections, but bacteria develop resistance against the antibiotics. 
Slika 2 – Kako se širi odpornost proti antibiotikom 9 Antibiotiki so zdravilo za bakterijske okužbe, toda bakterije razvijejo odpornost proti njim.
Overuse or misuse of antibiotics accelerates the development of resistance. 
Prekomerna ali nepravilna uporaba antibiotikov pospeši razvoj odpornosti.
The main risk of getting infected with a resistant superbug is in a healthcare facility. 
Mesto, kjer je nevarnost okužbe z odporno multirezistentno bakterijo največja, je zdravstvena ustanova.